NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-01

Study Completion Date

2018-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1 placebo-controlled biomarker study of NP001 in individuals with Alzheimer's Disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

NCT07236190

Alzheimer Disease Mild Cognitive Impairment (MCI) Subjective Cognitive Complaints (SCCs)

NOT_YET_RECRUITING PHASE1/PHASE2

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453

Alzheimers Disease

TERMINATED PHASE2/PHASE3

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511

Alzheimers Disease

TERMINATED PHASE2/PHASE3

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

NCT05318976

Alzheimer Disease Dementia Brain Diseases +7 more

COMPLETED PHASE2

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00667810

Alzheimer Disease

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Abnormal inflammatory monocytes/macrophages, systemically and locally in the central nervous system (CNS), are implicated in the neuro-inflammatory process seen in Alzheimer's disease. NP001 is a novel immune regulator of inflammatory monocytes/macrophages.

Given the key role inflammatory monocytes/macrophages may play in the pathogenesis of AD, this study will assess the changes in inflammatory monocyte-associated biomarkers, including CD16 and HLA-DR, pre- and post- NP001.

This is a Phase 1 single-site, randomized, double-blind, placebo-controlled pilot biomarker study of a single dose of NP001 in individuals with mild-to-moderate Alzheimer's disease. Fourteen individuals will be enrolled and randomized 1:1 to NP001 and placebo. Drug or placebo will be given intravenously. Biomarkers will be measured at baseline and 1 and 7 days following infusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single-site, randomized, double-blind, placebo-controlled

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NP001

Group Type EXPERIMENTAL

NP001

Intervention Type DRUG

NP001

Placebo

Normal saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Normal saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NP001

Intervention Type DRUG

Placebo

Normal saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, 55 years of age or older,
2. Diagnosis of probable Alzheimer's disease using the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and Related Disorders Association criteria by Principal Investigator,
3. Score 14 to 24 (inclusive) on the Mini-Mental Status Examination,
4. Global Clinical Dementia Rating (CDR) Scale ≥ 0.5 or greater with CDR memory ≥ 0.5 or greater,
5. Score ≤ 4 or lower on the Hachinski Ischemic Scale,
6. Score ≤ 5 on the Geriatric Depression Scale (GDS),
7. Current (stable dose for 4 weeks or longer) or past treatment with acetylcholinesterase inhibitors, memantine, or cognitive enhancers are allowed,
8. Females must not be of childbearing potential (i.e., must be post-menopausal with cessation of menses for ≥ 12 months or have been surgically sterilized which includes hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or tubal ligation),
9. Males must agree not to engage in sexual relations with a woman of childbearing potential without effective means of birth control during the study and for 30 days after study drug administration. Must also agree to refrain from sperm donation from receipt of study drug and for 90 days thereafter.
10. Be capable of providing written informed consent using a form that has been approved by the IRB.
11. Have veins suitable for intravenous administration of study drug or alternatively, have a venous access device.

Exclusion Criteria

1. Diagnosis of another neurologic disorder which can mimic Alzheimer's disease including dementia with Lewy Bodies, frontotemporal dementia and normal pressure hydrocephalus,
2. Diagnosis of other neurologic disorders which can also impair cognition including stroke, MS, seizures, CNS tumors,
3. Uncontrolled major psychiatric disorder,
4. History of unstable medical illness in the 3 months prior to screening including emergent hospitalizations,
5. Diagnosis of any of the following disorders: systemic sclerosis/scleroderma, inflammatory bowel disease, systemic lupus erythematosus (SLE), rheumatoid arthritis, mixed connective tissue disease, polymyalgia rheumatica, giant cell arteritis, polymyositis, dermatomyositis, and psoriasis,
6. Active pulmonary disease under treatment including uncontrolled asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary infection in the last 3 months, or history of aspiration,
7. History of unexplained jaundice by subject report,
8. History of Hepatitis A, B, or C or HIV by subject report,
9. History of stem cell therapy,
10. History of immune modulator therapy (e.g., corticosteroids, IV immunoglobulin, immunosuppressive chemotherapeutic agents, plasma exchange, GM-CSF, MCSF, interferons, infliximab, natalizumab, fingolimod \[GILENYA\], masitinib, ibudilast, tofacitinib citrate \[XELJANZ\], or any other approved drugs intended to affect the immune system) within 12 weeks of Screening Visit. Locally-acting corticosteroids (inhaled, intranasal, and topical) are permitted,
11. Participation in an experimental drug trial (of agents other than immune modulators) within 12 weeks prior to Screening Visit. Observational trials with no intervention are acceptable provided permission from the other study sponsor is obtained in writing,
12. Systolic blood pressure \< 100 mm Hg or \> 160 mm Hg, diastolic blood pressure \> 98 mm Hg. Patients on stable treatment for at least 3 months for hypertension are allowed as long as they meet entry criteria,
13. Hematocrit \< 33%, platelet count \< lower limit of normal, or neutrophil count \< 1,500/mm3,
14. Estimated creatinine clearance (eCCr) \< 50 mL/minute by Cockcroft-Gault Formula,
15. Elevated aspartate aminotransferase (AST) or alanine aminotransferance (ALT) greater than 3 times the upper limit of normal,
16. Pregnant or lactating females,
17. Have any condition which, in the opinion of the investigator, would put the subject at risk by participating in this study.

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No